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Social Media 
New study @JAACAP finds relationships between #polygenic susceptibility for #ADHD and 
cognition and brain morphological differences at caudate and total brain volumes in  
schoolchildren from @GenerationR_010   
 
Lay Summary 
Our results based on data from schoolchildren participating in the Generation R Study (The 
Netherlands) suggest that genetic susceptibility for attention-deficit hyperactivity disorder 
(ADHD) and cognition manifest early in life by influencing brain structure. Interestingly, genetic 
risk for ADHD was related to smaller caudate nucleus volume, a region previously associated 
with this disorder.  
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ABSTRACT 
Objective: To examine the relationship between polygenic scores (PGS) for five major 
psychiatric disorders and two cognitive traits with brain MRI morphological measurements in a 
large population-based sample of children. Additionally, we tested whether differences in brain 
morphology mediated associations between PGS for psychiatric disorders and related behavioral 
phenotypes.  
Method: The participants included 1,139 children from the Generation R Study assessed at 10 
years-of-age with genotype and neuroimaging data available. PGS were calculated for 
schizophrenia, bipolar disorder, major depression disorder, attention-deficit hyperactivity 
disorder (ADHD), autism spectrum disorder (ASD), intelligence and educational attainment 
(EA) using results from the latest genome-wide association studies. Image processing was 
performed using FreeSurfer to extract cortical and subcortical brain volumes.  
Results:  Higher genetic susceptibility for ADHD was associated with smaller caudate volume 
(strongest prior=0.01: β =-0.07, P= 0.006). Within boys, mediation analyses estimates suggested 
found that 11% of the association between the polygenic score for ADHD and attention problems 
was mediated by differences in caudate volume (n=535), while mediation was not significant in 
girls or the entire sample. PGS for EA and intelligence showed positive associations with total 
brain volume (TBV) (strongest prior=0.5: β =0.14, P=7.12x10-8; and β =0.12, P=6.87x10-7, 
respectively).  
Conclusions: Our findings indicate that the neurobiological manifestation of polygenic 
susceptibility for ADHD, EA, and intelligence involve early morphological differences in 
caudate and total brain volumes in childhood. Furthermore, the genetic risk for ADHD may 
influence attention problems via the caudate nucleus in boys. 
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INTRODUCTION 
Findings from genome-wide association studies (GWAS) indicate that multiple common genetic 
variants of small effect contribute to the etiology of psychiatric disorders, implying a highly 
polygenic architecture.1 However, it remains largely unknown how these common genetic 
variants ultimately contribute to the development of psychiatric symptoms.  
Polygenic scores (PGS) are increasingly being used to index individual genetic susceptibility for 
a given disorder or trait and explore shared genetic influences across phenotypes to improve 
understanding of disease etiology.2 Studies in childhood have shown that the polygenic risk for 
schizophrenia is associated with lower cognitive abilities, greater social impairments, more 
behavioral problems, and psychopathology.3–5 Interestingly, previous work from our group found 
that genetic susceptibility for educational attainment (years of schooling) was inversely related to 
child behavioral problems.4 In a large prospective study, polygenic risk for major depressive 
disorder was shown to be associated with emotional problems in adulthood, but not earlier in 
life.6 Similarly, genetic risk for bipolar disorder has been studied in adult samples. suggesting an 
association with increased risk for different psychiatric disorders.7 Regarding child onset 
psychiatric disorders, PGS for attention-deficit hyperactivity disorder (ADHD) have been 
associated with inattentive and hyperactive-impulsive traits, worse educational outcomes and 
lower IQ in children and adolescents from the general population.8,9  
Since genetic susceptibility to psychopathology and cognitive function has been linked to 
behavior,4 it could imply that heritable neurobiological mechanisms are at play in the early 
presentation of symptoms. Within this context, it is well established that brain morphology 
during development is highly influenced by genetic factors.10 Furthermore, widespread 
morphological brain abnormalities have been associated with the pathophysiology of major 
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psychiatric disorders.11–15 Although both genetic and environmental factors can account for these 
brain abnormalities, we expect that genetic susceptibility for psychiatric disorders are associated 
with variations in brain morphology. Indeed, several studies report relationships between PGS 
for psychiatric disorders and structural brain MRI measurements in adults using medium to large 
sample sizes within the context of the field of imaging genetics.16–19 Higher genetic risk for 
schizophrenia was related to total brain volume in both patients with schizophrenia (N=152) and 
controls (N=142),16 although this finding was not replicated using two large general population-
based samples (N=763 and N=707).17 Other studies in healthy populations have related 
polygenic risk for both schizophrenia and bipolar disorder with reduced globus pallidus and 
amygdala volumes (N=274).18 However, one of the largest studies to date did not find evidence 
for associations between polygenic risk for schizophrenia, bipolar disorder or major depression 
and subcortical brain volumes using data from the UK Biobank study (N=978).19 Furthermore, to 
our knowledge, no study has yet been conducted in a pediatric MRI sample representative of the 
general population. Thus, whether associations of polygenic susceptibility for major psychiatric 
disorders and brain morphology are present earlier in life is largely unclear. Since ASD and 
ADHD are child-onset psychiatric disorders, the study of polygenic risk for these traits in 
pediatric samples is particularly relevant. To date, this has been hampered by the lack of large-
scale imaging studies in children that include genetic data. 
Within this backdrop, it was the goal of our study to examine the association between polygenic 
susceptibility for five psychiatric disorders and two cognitive outcomes with global and 
subcortical brain volumes in a large population-based sample of school-age children. As a 
secondary aim, we investigated the potential mediating role of brain morphological variation on 
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associations between polygenic scores for psychiatric disorders and related behavioral 
phenotypes. 
We hypothesized that polygenic susceptibility for schizophrenia, bipolar disorder, major 
depression disorder, autism spectrum disorders and ADHD are associated with brain 
morphological characteristics that overlap with brain abnormalities consistently reported in 
patients affected by these disorders. Regarding EA and intelligence, we hypothesized that PGS 
for these traits positively associated with global brain morphology measures.  
 
METHOD 
Study population 
Participants were drawn from the Generation R Study, an ongoing population-based cohort 
aimed to study many domains of child development.20 As part of the cohort’s magnetic 
resonance imaging (MRI) study, 3,992 children were scanned between March 2013 and 
November 2015 corresponding to the 9-to-11 years-of-age Generation R visit.21 Of these 
children, 3,937 had images that were reconstructed using FreeSurfer (version 6.0 
[http://surfer.nmr.mgh.harvard.edu/]). One-hundred thirty-one children were excluded due to 
either the use of a different sequence (n=22), dental braces (n=87), and the presence of incidental 
findings (n=22).22 From the remaining 3,806, 620 scans were excluded due to data rated as 
unusable after visual inspection of segmentation quality. This left 3,186 children with good 
quality MRI data. Of these, genotype data was available for 1,189 children with European 
ancestry. Finally, relatedness and genotype quality resulted in an additional exclusion of 50 
children. Thus, the final sample included 1,139 participants (see flowchart in Figure S1, 
available online). 
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The study protocol was approved by the Medical Ethics Committee of the Erasmus Medical 
Centre. Written informed consent was obtained from the legal representatives of all participants. 
MRI 
To familiarize participants with the MRI scanning environment, all children underwent a mock 
scanning session. Structural MRI scans were obtained on a 3-Tesla scanner (Discovery 
MR750W, GE Worldwide, Milwaukee, USA). Whole-brain high-resolution T1-weighted 
inversion recovery fast spoiled gradient recalled (IR-FSPGR) sequences were obtained using an 
8-channel head coil. The scan parameters were: TR = 8.77 ms, TE = 3.4 ms, TI=600ms, flip 
angle = 10º, field of view= 220mm x 220mm, acquisition matrix= 220 x 220, asset acceleration 
factor = 2, b = 900 s/mm2, 230 contiguous slices with a thickness of 1.0 mm, and in-plane 
resolution = 1.0 × 1.0 mm. Further details on the design and protocol of the Generation R 
cohort’s MRI study can be found elsewhere.21  
Cortical reconstruction and volumetric segmentation were carried out with the FreeSurfer image 
analysis suite version 6.0.23 Specifically, automatic parcellation and segmentation protocols were 
conducted using the recon-all stream to obtain total, cortical, and subcortical brain volumes. All 
images were inspected for surface reconstruction accuracy using automated and manual 
method.24 Based on previous research investigating brain abnormalities in psychiatric 
disorders,11–15 ten volumetric brain measures were studied as outcomes; including total brain 
volume (TBV), cortical gray matter (GM), total white matter (WM), subcortical GM, ventricular 
volume and cerebellum as global segmented brain measurements; and amygdala-hippocampus 
complex, caudate, putamen and thalamus as subcortical brain volumes. Correlations between the 
brain measurements are shown in Figure S2, available online. 
  
10 
 
Genotyping  
DNA samples were collected from cord blood at birth or from venipuncture during a visit to the 
research center on Illumina 610K and 660K SNP arrays depending on collection time (Illumina, 
San Diego, CA, USA). Further details on genotype calling procedures in Generation R Study can 
be found elsewhere.25 Information on quality control procedures of the genotype data and 
principal component analysis can be in in Supplementary Material (see Supplement 1, available 
online). 
Polygenic scoring 
Only participants with European ancestry were selected for the polygenic scoring. Genotype data 
that passed quality control was used to compute polygenic scores based on GWAS results for 
five psychiatric traits, including schizophrenia (SCZ), bipolar disorder (BD), major depression 
(MDD), attention-deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) 
from the Psychiatric Genomics Consortium. In addition, we calculated polygenic scores for 
educational attainment (EA) and intelligence. Supplementary Table S1 (available online) 
provides an overview of the GWAS studies used for PGS calculation. For intelligence, we 
repeated the GWAS meta-analysis after exclusion of Generation R to ensure independence of 
discovery and target sample.  
Polygenic scores were computed using LDpred.26 This polygenic scoring method infers the 
posterior mean effect size of each marker by using a prior on effect size distribution and LD 
information from a reference genotype panel. The LDpred algorithm has improved prediction 
accuracy compared to traditional methods. Six PGS were computed for each trait corresponding 
to six priors that determined the proportion of SNPs with a causal effect (0.01, 0.05, 0.1, 0.5, 1 
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and infinitesimal). All polygenic scores were standardized to a mean of 0 and a standard 
deviation of 1. Correlations between the PGS are shown in Figure S3, available online. 
 
Statistical Analysis 
Multiple linear regression analyses were conducted using R statistical software package, version 
3.3.1 (http: www.r-project.org/). To examine whether genetic susceptibility for major psychiatric 
disorders and cognition is related to brain morphology, each PGS was tested for association with 
each brain measure individually. In these models, brain measurements were assigned as the 
dependent variables with PGS for SCZ, BD, ADHD, ASD, EA or intelligence generated at six 
LDpred priors as independent variables. Models with TBV as outcome were adjusted by sex, age 
and four genetic principal components. Models for the rest of brain measurements were 
additionally adjusted by total intracranial volume.  
We corrected for multiple testing across all PGS, generated at six different priors, tested for 
association with ten brain measurements using the false discovery rate (FDR) method.27 Results 
at PFDR<0.05 were considered statistically significant. 
For statistically significant associations showing a consistent pattern of results, we performed 
mediation analyses to examine whether differences in the associated brain regions mediated 
associations between the PGS and the phenotypic manifestation of the PGS trait. Multiple linear 
regressions analyses were conducted to examine associations between PGS, brain measurements 
and behavioral phenotypes adjusting for the same covariates included in the primary analyses 
and age at behavioral assessment. The direct effect (DE), indirect effect (IE), and total effect 
(TE) were estimated using the “mediation” package in R. As long as the assumptions of the 
mediation analysis are met, the DE represents the effect of genetic susceptibility on behavioral 
phenotypes after controlling for variation in brain morphology, and the IE represents the 
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estimated effect of polygenic susceptibility operating through brain morphology.28 The 
proportion of mediation by brain morphology can be calculated as the ratio of IE to TE. Given 
the data available in Generation R, mediation analyses were only feasible for associations with 
PGS for psychiatric disorders for which behavioral data was assessed when children were 
between 8-11 years of age (Mean=9.7, SD=0.23, range=8.85-11.54) using the (CBCL/6-18).29 
Genetic, neuroimaging and behavioral data were available for 1053 participants. Further details 
on behavioral assessment can be found elsewhere.21 For psychiatric disorders with sex 
differences in prevalence, we also conducted stratified analysis by sex. 
To elucidate whether each cognitive trait independently contributed to variation in the brain 
measurement, we performed sensitivity analyses for the analyses between the PGS for EA and 
intelligence with TBV, mutually adjusting using the PGS for intelligence and EA, respectively. 
RESULTS 
Sample characteristics 
A total of 1,139 children were included in the present study of whom 49.30% (n=561) were 
females, and the mean age was 10.16 years (SD=0.60, range= 8.72-11.99).  
Effects of PGS on brain morphology 
Figure 1 summarizes associations between the PGS for psychiatric disorders and cognition 
calculated at six priors and brain volumes. Full results for these associations are detailed in Table 
S2, available online.  
No significant associations were observed between PGS for SCZ and BD and brain 
measurements.  
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Higher genetic susceptibility for MDD was consistently related to smaller TBV showing the 
strongest association for the infinitesimal prior (β =-0.07, SE=0.03; Puncorrected = 0.009). PGS for 
MDD also showed negative associations with total WM (prior=0.01: β =-0.03, SE=0.01, 
Puncorrected=0.043), cerebellum volume (prior=0.5: β =-0.05, SE=0.02, Puncorrected =0.042; prior=1: 
β =-0.05, SE=0.02, Puncorrected =0.040), and thalamus volume (prior=0.01: β =-0.05, SE=0.02, 
Puncorrected =0.009). However, following FDR-correction none of these associations remained 
significant. 
PGS for ADHD were associated with smaller TBV and caudate volume across all priors although 
associations did not reach statistical significance for prior 0.01 in the case of TBV, and prior 1 in 
the case of caudate volume. The strongest association with TBV was observed at the 
infinitesimal prior (β =-0.07, SE=0.03; Puncorrected = 0.006) while the strongest association with 
caudate volume was observed at prior 0.01 (β =-0.08, SE=0.03; Puncorrected = 7.49×10-4), and 
remained significant after FDR-correction. 
PGS for ASD showed positive associations with TBV at all priors except at prior 0.01 which did 
not reach significance, but did show the same direction of effect. The largest magnitude of the 
association was observed at prior 1 (β =0.07, SE=0.03; Puncorrected=7.75×10-3). These associations 
did not surpass FDR-correction.  
The EA PGS were consistently associated with larger TBV (strongest prior 0.5: β=0.14, 
SE=0.03, Puncorrected=7.12×10-8) and remained significant after FDR-correction. Associations at 
prior 0.05 did not reach significance but showed the same direction of effect. Higher genetic 
susceptibility for EA was also associated with larger volumes of subcortical GM (prior=0.05: 
β=0.04, SE=0.02, Puncorrected=0.046), cerebellum (prior=0.1: β=0.05, SE=0.02, Puncorrected=0.047), 
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putamen (prior=0.05: β=0.06, SE=0.03, Puncorrected=0.016) and thalamus at multiples priors 
(strongest prior=1: β=0.05, SE=0.02, Puncorrected=0.012).  
Higher genetic susceptibility for intelligence was significantly related to larger TBV for most of 
the priors, used even after FDR-correction (strongest prior 0.5: β=0.12, SE=0.03; Puncorrected = 
6.87×10-7). Other associations not surviving FDR-correction included a positive association with 
subcortical GM (Infinitesimal prior: β =0.04, SE=0.02, Puncorrected=0.024) and positive 
associations with cerebellum volume (priors 0.01 and 0.05: β=0.07, SE=0.02, Puncorrected =0.003).  
Mediation analysis  
Only the association between polygenic risk for ADHD and caudate volume survived FDR-
correction, therefore, we tested whether caudate volume mediated the association between 
polygenic risk for ADHD and the attention problems CBCL syndrome scale. The caudate 
nucleus met the conditions to act as a mediator, since it showed a negative significant association 
with attention problems (β=-0.06, SE=0.00, P=0.029). Similarly, polygenic risk for ADHD was 
significantly associated with attention problems (β=0.12, SE=0.00, P=5.36x10-5). However, 
mediation was 4.6% and not significant within the entire sample (Figure 2). In analyses stratified 
by sex, mediation was significant only in boys indicating that 11% of the association between 
polygenic risk for ADHD (prior=0.01) and attention problems may be mediated by differences in 
caudate volume (Figure 2). 
Sensitivity analysis  
Analyses mutually adjusting for polygenic susceptibility for EA and intelligence at prior 0.05 
showed that the PGS for both traits were independently associated with TBV (PGS for EA: 
β=0.10, SE=0.03; P=2.6×10-4; PGS for intelligence= β=0.08, SE=0.03; P=0.003). 
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DISCUSSION 
We examined whether polygenic susceptibility for psychiatric disorders and cognition was 
associated with brain morphology in children. We found a consistent pattern of results across 
priors indicating that the polygenic risk for ADHD was negatively associated with caudate 
volume, with the finding with at prior of 0.01 surviving multiple testing correction. Polygenic 
susceptibility for intelligence and EA showed a positive relationship with TBV that was 
consistent across all priors used, although generally not significant for the more stringent priors 
(i.e. 0.05 and 0.01). Polygenic risk for SCZ and BD did not show significant associations with 
brain morphology, however, several brain measurements were related to PGS for MDD and 
ASD, although none of these associations survived multiple testing correction. These findings 
indicate the neurobiological manifestation of polygenic susceptibility for ADHD, intelligence, 
and EA involves early morphological differences in caudate and total brain volume during 
development. 
Whole-brain and caudate volume reductions have been related to ADHD in a recent mega-
analysis.14 Given the high heritability of ADHD,30 we expected that regions previously 
associated with the disorder would also be associated with polygenic risk for ADHD. To the best 
of our knowledge, this is the first study providing evidence indicating that polygenic risk for 
ADHD may be, at least partially, underlying TBV and caudate reductions in childhood. These 
findings are particularly relevant in the case of the caudate volume reduction, one of the most 
replicated findings in ADHD.31 Interestingly, our results suggest that reduced caudate volume 
may be mediating the association between polygenic risk for ADHD and attention problems in 
boys. ADHD is 2 to 9 times more prevalent in boys during childhood and adolescence.32 Gender 
differences in brain morphology have been used to investigate whether ADHD-related brain 
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abnormalities are more pronounced in males compared to females. Although caudate volume did 
not show sex effects in the mega-analysis conducted by Hoogman et al,14 another study 
examining volume and shape of the basal ganglia observed smaller caudate volumes in boys with 
ADHD compared to male controls and no differences among girls.33 Similarly, smaller caudate 
volumes have been found in adult male ADHD patients compared to male controls, while no 
differences were observed among females.34 Our findings are in line with these studies 
supporting that different genetically-influenced neurobiological mechanisms may be operating in 
males and females in the context of ADHD.  
The EA polygenic scores were associated with larger TBV. Intracranial volume has been 
previously related to EA genetic variants by applying LD Score regression methodology.35 
Genetic variants for EA or other traits, may affect TBV directly, through direct gene expression, 
via gene-environment interaction or correlation mechanisms, or through intermediate 
phenotypes. Remarkably, an important number of SNPs related to EA are located within 
genomic regions regulating gene expression in the fetal brain and genes mainly expressed in 
neural tissue.35 These genes are especially active during the prenatal period and enriched for 
biological pathways involved in neural development.35 Thus, it is likely that polygenic 
susceptibility for EA includes variants that directly promote optimal brain development. Another 
possibility would be that EA genetic variants could influence brain morphology through 
environmental exposures that positively affect brain development, which would imply gene-
environment correlation effects. In fact, children with higher genetic loading for EA tend to be 
raised in socioeconomically advantaged environments,36 which positively impacts brain 
development.37 Finally, it is also important to note that genetic associations with EA may be 
mediated by other phenotypes such as intelligence or personality traits which are considered 
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intermediate phenotypes for EA.38 In addition, higher genetic loading for EA was nominally 
associated with larger thalamus volumes at multiple priors. The thalamus is a major hub in the 
brain, relaying multimodal information covering a wide range of cognitive functions, including 
learning, memory, inhibitory control, decision-making, control of visual orienting responses and 
attention.39 Thus, a relationship between polygenic susceptibility for cognitive functions relevant 
for education attainment with increased volume of the thalamus is neurobiologically plausible.  
Not surprisingly, our findings on polygenic susceptibility for intelligence and EA largely overlap 
in terms of strength of the association and variance explained of TBV. Similarly to EA, genetic 
variants related to intelligence were identified in genes predominantly expressed in brain tissue.40      
Interestingly, polygenic susceptibility for both EA and intelligence influenced TBV 
independently of each other. Since the correlation between the PRS for EA and intelligence were 
not extremely strong (Figure S3, available online), we speculate that genetic variants related to 
these traits may act through different pathways. Studies have shown that TBV is positively 
correlated with intelligence, accounting for about 16% of the variance in IQ.41 Furthermore, our 
results indicate a shared genetic overlap between IQ and brain size, which is in line with twin 
studies suggesting that the association between these phenotypes is mainly of genetic origin.42  
Contrary to our hypothesis, polygenic risk for SCZ was not associated with brain morphological 
variation between the ages of 9-to-11 years. This is in line with previous research in adults.17,19 
However, this null finding was surprising, as we found an association between the PGS for SCZ 
and internalizing symptoms, and especially thought problems.4 Behavioral effects of polygenic 
risk for SCZ must have neural correlates that we were unable to detect for several potential 
reasons. First, it is possible that the neural correlates of SCZ PGS are related to other 
neurobiological phenotypes not quantified in our study. This would not be the case for white 
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matter measurements including global and tract-specific fractional anisotropy and mean 
diffusivity that were tested for association with polygenic risk for SCZ in this sample, revealing 
negative results.43 Also, polygenic risk for SCZ has been associated with functional brain 
parameters, such as brain activation patterns detectable with fMRI during cognitive tasks in 
adolescents.44,45 Second, brain structural abnormalities related to genetic risk for schizophrenia 
may only be detectable in young individuals beginning in the prodromal phase, when the illness 
has begun to show clinical manifestations. These finding become ‘unmasked’ as the illness 
progresses, making it very difficult to observe in general population samples, especially early in 
life. Finally, genetic risk for SCZ has been related to nonparticipation in a large longitudinal 
population-based cohort studies,46 implying that individuals at high genetic risk may be 
underrepresented. This would lead to underestimating effects of these genetic variants on 
neurodevelopmental outcomes. However, PGS for SCZ were very similar within the Generation 
R participants with EU ancestry comparing those included versus excluded in the current study 
(Table S3, available online). 
Other interesting findings, albeit not surpassing multiple testing correction, include positive 
relationships between PGS for ASD and TBV, and negative associations between MDD PGS and 
TBV. Converging evidence points to an increased brain size as a characteristic brain abnormality 
of young children with ASD.47 Our results suggest that this association may be accounted by 
common genetic variants increasing the risk for ASD. Although it may seem counterintuitive that 
polygenic risk for ASD shows the same direction of effects on TBV as PGS for EA and 
intelligence, it has been shown that polygenic risk for these traits is highly correlated and that 
genetic risk for ASD may act through different etiological pathways.48 Regarding MDD PGS, 
widespread GM and subcortical volume reductions have been reported in individuals affected by 
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MDD.49 Comparatively, less research has been conducted on global structural brain measures 
such as TVB. Overall, further research is needed to confirm these potential associations. 
Our results should be interpreted in the context of several strengths and limitations. The strengths 
of the current study include the large sample size and homogeneity with respect to recruitment, 
exclusion criteria, scanner, image acquisition and pre-processing methods, which is especially 
valuable in the imaging genetics field. That said, the current sample is adequate for detecting 
significant effect sizes above 0.08 at 80% power, thus, reported smaller effect sizes, which 
correspond to negative findings, should be interpreted with caution. The main limitation of the 
study is the cross-sectional design. Studies including brain morphological measurements at 
multiple time points are needed to examine whether polygenic risk for psychiatric disorders and 
cognition contribute to changes in developmental trajectories. Another limitation is that the 
polygenic scores typically explain only a small proportion of the total phenotypic variance of 
complex traits.1,2 It is also important to notice that predictive accuracy of PGS is related to 
sample size in the discovery sample, which substantially varies among the different traits for 
PGS examined in the current study.50 This should be considered when comparing results for the 
different traits examined. Nevertheless, we used summary statistics from the most recent, and 
thus more powerful GWAS conducted on psychiatric disorders to date, which represents an 
advantage over previous studies using PGS based on GWAS conducted on smaller samples.  
To conclude, we found a relationship between polygenic susceptibility for intelligence and EA 
and TBV in school-age children. We also found effects of ADHD polygenic risk for caudate 
volume. Interestingly, we found evidence for mediation only in boys, where differences in the 
caudate volume accounted for 11% of the association between polygenic risk for ADHD and 
attention problems at 9 years-of-age. Overall, our findings provide molecular genetic evidence 
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for the relationship between polygenic susceptibility for cognition and ADHD with early 
differences in brain morphology.  
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Figure Legends 
 
Figure 1. Associations between polygenic scores for schizophrenia (SCZ), bipolar disorder 
(BD), major depression disorder (MDD), attention-deficit hyperactivity disorder (ADHD), 
autism spectrum disorder (ASD), educational attainment (EA) and intelligence computed at six 
priors (0.01, 0.05, 0.1, 0.5, 1 and infinitesimal) and brain volumes adjusted for sex, age, total 
intracranial volume (except associations with TBV) and the first four genetic components 
(n=1139). P-uncorrected values <0.05 are indicated with asterisk (*), P-FDR<0.05 are indicated 
with a cross (X). 
 
Figure 2. Mediation analysis of the estimated effect (95% CIs) of polygenic risk for ADHD 
(prior=0.01) on attention problems (CBCL syndrome scale reported by mothers) through caudate 
volume in the entire sample (n=1053) and stratified by sex (boys, n=535; girls, n=518). The 
figure shows caudate volume as a potential mediator, the estimates of indirect and direct effect, 
and the proportion of mediation. All models were adjusted for age at MRI scan, age at CBCL 
administration, total intracranial volume and the first four genetic components. 
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Supplement 1. Genotyping  
DNA samples were collected from cord blood at birth or from venipuncture during a visit to the 
research center on Illumina 610K and 660K SNP arrays depending on collection time (Illumina, 
San Diego, CA, USA). Further details on genotype calling procedures in Generation R Study can 
be found elsewhere (Medina-Gomez et al. 2015). Quality control at the genotype and individual 
data level was conducted using PLINK (v1.9) (Purcell et al. 2007). Genotype data quality control 
included filtering variants for minor allele frequency (MAF< 1%), Hardy-Weinberg 
disequilibrium (HWE, P<1x10-5) and missing rate (>5%). Individuals were filtered on 
relatedness (pairwise identity-by-descent (IBD) >0.185), genetic and phenotypic sex mismatch, 
and genotype quality (<5% missing). Polygenic scoring was performed on genotyped SNPs only.  
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Figure S1. Flow chart of the study population. 
 
 
 
Scanned Participants 
N=3992 
N=3937 
Excluded (n=55) 
- Unable to reconstruct FreeSurfer data from 
the raw T1-weighted image  
N=3186 
Imaging exclusion criteria (n=751) 
- Different sequence (n=22) 
- Braces (n=87) 
- Incidental findings (n=22) 
- Poor FreeSurfer reconstruction (n=620) 
N=1189 
Excluded (n=1997) 
- No genetic data 
N=1139 
Excluded (n=50) 
- Relatedness 
33 
 
Figure S2. Pearson correlations between brain MRI measurements (N=1139). Intensity of the color of 
shaded boxes indicates the magnitude of the correlation. Colored boxes indicate significant correlations at 
P<0.05.  
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Figure S2. Pearson correlations between the polygenic scores for schizophrenia (SCZ), bipolar disorder 
(BD), major depression disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), autism 
spectrum disorders (ASD), educational attainment (EA) and intelligence computed at six priors (0.01, 
0.05, 0.1, 0.5, 1 and infinitesimal) (N=1139). Intensity of the color of shaded boxes indicates the 
magnitude of the correlation. Colored boxes indicate significant correlations at P<0.05.  
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Table S1. Summary statistics used to calculate polygenic scores were obtained from the following GWAS. Number of SNPs (N SNPs) included in the 
PGRS for each trait is indicated. 
Consortium/Cohorts  Trait N N SNPs Reference 
PGC Schizophrenia 77.096 481,162 (Ripke et al. 2014)    
PGC Bipolar Disorder 16.731 473,445 (PGC Bipolar Disorder Working Group 2011)  
PGC MDD 307.354 480,813 (Wray et al. 2018)  
PGC ADHD 55.374 450,347 (Demontis et al. 2017) 
PGC ASD 15.954 480,374 (PGC Autism Spectrum Disorders Working Group 2017)  
SSGAC Educational Attainment 293,723 479,695 (Okbay et al. 2016)   
CTG Intelligence 269.867 458,676 (Savage et al. 2018)  
Note: PGC, Psychiatric Genomics Consortium; SSGAC, Social Science Genetic Association Consortium; CTG, Complex Trait Genetics. 
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Table S2. Association results between polygenic scores for schizophrenia (SCZ), bipolar disorder (BD), major depression disorder (MDD), attention-
deficit/hyperactivity disorder (ADHD), autism spectrum disorders (ASD), educational attainment (EA) and intelligence computed at six priors (0.01, 0.05, 0.1, 0.5, 1 
and infinitesimal) and brain measurements including: total brain volume (TBV), cortical gray matter (GM), total white matter (WM), subcortical GM, total 
ventricular volume, cerebellum volume, amygdala-hippocampus complex, caudate volume, putamen volume and thalamus volume. Models with TBV as outcome 
were adjusted by sex, age and four genetic principal components. Models for the rest of brain measurements were additionally adjusted by total intracranial volume. 
Significant results are indicated with an asterisk.  
PGS Brain measurement β SE P-uncorr. P-FDR ΔR² 
SCZ (prior= 0.01) 
TBV 0.006 0.025 7.96E-01 9.47E-01 -0.001 
Cortical GM 0.011 0.015 4.47E-01 7.78E-01 0.000 
Total WM -0.015 0.014 2.91E-01 6.73E-01 0.000 
Subcortical GM -0.019 0.018 2.97E-01 6.73E-01 0.000 
Total Ventricular volume -0.040 0.027 1.45E-01 6.73E-01 0.001 
Cerebellum volume -0.028 0.023 2.16E-01 6.73E-01 0.000 
Amygdala-hippocampus complex 0.005 0.020 8.11E-01 9.56E-01 0.000 
Caudate volume -0.023 0.025 3.54E-01 6.95E-01 0.000 
Putamen volume -0.046 0.025 7.11E-02 5.57E-01 0.001 
Thalamus volume 0.009 0.022 6.38E-01 8.99E-01 0.000 
SCZ (prior= 0.05) 
TBV -0.028 0.025 2.66E-01 6.73E-01 0.000 
Cortical GM 0.009 0.015 5.33E-01 8.46E-01 0.000 
Total WM -0.006 0.014 6.72E-01 9.12E-01 0.000 
Subcortical GM -0.002 0.018 9.17E-01 9.98E-01 0.000 
Total Ventricular volume -0.039 0.027 1.54E-01 6.73E-01 0.001 
Cerebellum volume -0.021 0.023 3.67E-01 7.14E-01 0.000 
Amygdala-hippocampus complex 0.024 0.020 2.88E-01 6.73E-01 0.000 
Caudate volume -0.005 0.025 8.39E-01 9.66E-01 -0.001 
Putamen volume -0.008 0.025 7.61E-01 9.30E-01 -0.001 
Thalamus volume 0.003 0.022 8.97E-01 9.98E-01 0.000 
SCZ (prior= 0.1) 
TBV -0.011 0.025 6.50E-01 9.00E-01 -0.001 
Cortical GM 0.006 0.015 7.07E-01 9.23E-01 0.000 
Total WM 0.004 0.014 7.63E-01 9.30E-01 0.000 
Subcortical GM 0.008 0.018 6.47E-01 9.00E-01 0.000 
Total Ventricular volume -0.034 0.027 2.07E-01 6.73E-01 0.000 
Cerebellum volume -0.013 0.023 5.72E-01 8.68E-01 0.000 
Amygdala-hippocampus complex 0.010 0.020 6.60E-01 9.02E-01 0.000 
Caudate volume 0.001 0.025 9.75E-01 9.98E-01 -0.001 
Putamen volume 0.013 0.025 6.23E-01 8.90E-01 0.000 
Thalamus volume 0.015 0.022 4.70E-01 7.84E-01 0.000 
SCZ (prior= 0.5) 
TBV -0.008 0.025 7.44E-01 9.29E-01 -0.001 
Cortical GM 0.012 0.015 4.02E-01 7.46E-01 0.000 
Total WM -0.005 0.014 7.12E-01 9.23E-01 0.000 
Subcortical GM 0.013 0.018 4.65E-01 7.84E-01 0.000 
Total Ventricular volume -0.013 0.027 6.31E-01 8.95E-01 -0.001 
Cerebellum volume -0.005 0.023 8.22E-01 9.62E-01 -0.001 
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Amygdala-hippocampus complex 0.031 0.020 1.65E-01 6.73E-01 0.000 
Caudate volume -0.013 0.025 5.85E-01 8.75E-01 0.000 
Putamen volume 0.028 0.025 2.72E-01 6.73E-01 0.000 
Thalamus volume 0.010 0.022 6.08E-01 8.90E-01 0.000 
SCZ (prior= 1) 
TBV -0.008 0.025 7.60E-01 9.30E-01 -0.001 
Cortical GM 0.009 0.015 5.59E-01 8.68E-01 0.000 
Total WM -0.006 0.014 6.83E-01 9.16E-01 0.000 
Subcortical GM -0.002 0.018 8.95E-01 9.98E-01 0.000 
Total Ventricular volume -0.017 0.027 5.29E-01 8.45E-01 0.000 
Cerebellum volume -0.015 0.023 5.02E-01 8.14E-01 0.000 
Amygdala-hippocampus complex 0.022 0.020 3.12E-01 6.73E-01 0.000 
Caudate volume -0.028 0.025 2.56E-01 6.73E-01 0.000 
Putamen volume -0.001 0.025 9.65E-01 9.98E-01 -0.001 
Thalamus volume 0.007 0.022 7.42E-01 9.29E-01 0.000 
SCZ (Infinitesimal prior) 
TBV -0.009 0.025 7.23E-01 9.24E-01 -0.001 
Cortical GM -0.001 0.015 9.58E-01 9.98E-01 0.000 
Total WM -0.016 0.014 2.62E-01 6.73E-01 0.000 
Subcortical GM -0.001 0.018 9.38E-01 9.98E-01 0.000 
Total Ventricular volume -0.019 0.027 4.93E-01 8.06E-01 0.000 
Cerebellum volume -0.005 0.023 8.27E-01 9.64E-01 -0.001 
Amygdala-hippocampus complex 0.029 0.020 1.82E-01 6.73E-01 0.000 
Caudate volume -0.035 0.025 1.55E-01 6.73E-01 0.001 
Putamen volume 0.000 0.025 9.98E-01 9.98E-01 -0.001 
Thalamus volume 0.012 0.022 5.68E-01 8.68E-01 0.000 
BD (prior= 0.01) 
TBV 0.029 0.025 2.42E-01 6.73E-01 0.000 
Cortical GM 0.017 0.015 2.57E-01 6.73E-01 0.000 
Total WM -0.003 0.014 8.02E-01 9.49E-01 0.000 
Subcortical GM 0.014 0.018 4.46E-01 7.78E-01 0.000 
Total Ventricular volume -0.036 0.027 1.91E-01 6.73E-01 0.001 
Cerebellum volume -0.004 0.023 8.45E-01 9.70E-01 -0.001 
Amygdala-hippocampus complex 0.022 0.020 3.18E-01 6.73E-01 0.000 
Caudate volume -0.025 0.025 3.10E-01 6.73E-01 0.000 
Putamen volume 0.026 0.025 3.07E-01 6.73E-01 0.000 
Thalamus volume 0.012 0.022 5.62E-01 8.68E-01 0.000 
BD (prior= 0.05) 
TBV 0.018 0.025 4.64E-01 7.84E-01 0.000 
Cortical GM 0.018 0.015 2.10E-01 6.73E-01 0.000 
Total WM -0.008 0.014 5.83E-01 8.74E-01 0.000 
Subcortical GM 0.002 0.018 9.00E-01 9.98E-01 0.000 
Total Ventricular volume -0.014 0.027 6.10E-01 8.90E-01 -0.001 
Cerebellum volume -0.001 0.023 9.80E-01 9.98E-01 -0.001 
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Amygdala-hippocampus complex 0.027 0.020 2.23E-01 6.73E-01 0.000 
Caudate volume -0.026 0.025 2.88E-01 6.73E-01 0.000 
Putamen volume -0.001 0.025 9.67E-01 9.98E-01 -0.001 
Thalamus volume 0.008 0.022 6.96E-01 9.23E-01 0.000 
BD (prior= 0.1) 
TBV 0.014 0.025 5.77E-01 8.68E-01 0.000 
Cortical GM 0.017 0.015 2.50E-01 6.73E-01 0.000 
Total WM -0.009 0.014 5.35E-01 8.46E-01 0.000 
Subcortical GM -0.001 0.018 9.56E-01 9.98E-01 0.000 
Total Ventricular volume -0.009 0.027 7.42E-01 9.29E-01 -0.001 
Cerebellum volume -0.002 0.023 9.44E-01 9.98E-01 -0.001 
Amygdala-hippocampus complex 0.028 0.020 2.11E-01 6.73E-01 0.000 
Caudate volume -0.026 0.025 2.97E-01 6.73E-01 0.000 
Putamen volume -0.009 0.025 7.37E-01 9.29E-01 -0.001 
Thalamus volume 0.006 0.022 7.58E-01 9.30E-01 0.000 
BD (prior= 0.5) 
TBV 0.010 0.025 6.94E-01 9.23E-01 -0.001 
Cortical GM 0.015 0.015 2.96E-01 6.73E-01 0.000 
Total WM -0.009 0.014 4.97E-01 8.10E-01 0.000 
Subcortical GM -0.002 0.018 9.01E-01 9.98E-01 0.000 
Total Ventricular volume -0.004 0.027 8.95E-01 9.98E-01 -0.001 
Cerebellum volume -0.001 0.023 9.58E-01 9.98E-01 -0.001 
Amygdala-hippocampus complex 0.029 0.020 1.95E-01 6.73E-01 0.000 
Caudate volume -0.024 0.025 3.36E-01 6.91E-01 0.000 
Putamen volume -0.013 0.025 6.23E-01 8.90E-01 0.000 
Thalamus volume 0.006 0.022 7.83E-01 9.44E-01 0.000 
BD (prior= 1) 
TBV 0.009 0.025 7.07E-01 9.23E-01 -0.001 
Cortical GM 0.015 0.015 3.04E-01 6.73E-01 0.000 
Total WM -0.010 0.014 4.92E-01 8.06E-01 0.000 
Subcortical GM -0.003 0.018 8.89E-01 9.98E-01 0.000 
Total Ventricular volume -0.003 0.027 9.17E-01 9.98E-01 -0.001 
Cerebellum volume -0.002 0.023 9.47E-01 9.98E-01 -0.001 
Amygdala-hippocampus complex 0.029 0.020 1.94E-01 6.73E-01 0.000 
Caudate volume -0.023 0.025 3.44E-01 6.91E-01 0.000 
Putamen volume -0.013 0.025 6.06E-01 8.90E-01 0.000 
Thalamus volume 0.005 0.022 7.93E-01 9.46E-01 0.000 
BD (Infinitesimal prior) 
TBV 0.000 0.025 9.90E-01 9.98E-01 -0.001 
Cortical GM 0.018 0.015 2.23E-01 6.73E-01 0.000 
Total WM -0.011 0.014 4.43E-01 7.78E-01 0.000 
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Subcortical GM 0.009 0.018 6.38E-01 8.99E-01 0.000 
Total Ventricular volume -0.016 0.027 5.66E-01 8.68E-01 -0.001 
Cerebellum volume 0.006 0.023 7.87E-01 9.44E-01 0.000 
Amygdala-hippocampus complex 0.040 0.020 7.29E-02 5.57E-01 0.001 
Caudate volume -0.024 0.025 3.37E-01 6.91E-01 0.000 
Putamen volume 0.013 0.025 6.23E-01 8.90E-01 0.000 
Thalamus volume 0.004 0.022 8.38E-01 9.66E-01 0.000 
MDD (prior= 0.01) 
TBV -0.030 0.025 2.31E-01 6.73E-01 0.000 
Cortical GM 0.000 0.015 9.81E-01 9.98E-01 0.000 
Total WM -0.028 0.014 4.31E-02* 4.64E-01 0.001 
Subcortical GM -0.030 0.018 1.00E-01 6.23E-01 0.001 
Total Ventricular volume -0.010 0.027 7.24E-01 9.24E-01 -0.001 
Cerebellum volume -0.015 0.023 5.26E-01 8.42E-01 0.000 
Amygdala-hippocampus complex 0.011 0.020 6.27E-01 8.93E-01 0.000 
Caudate volume -0.030 0.026 2.18E-01 6.73E-01 0.000 
Putamen volume -0.010 0.025 6.85E-01 9.16E-01 -0.001 
Thalamus volume -0.052 0.022 9.41E-03* 2.21E-01 0.002 
MDD (prior= 0.05) 
TBV -0.059 0.025 1.87E-02* 2.92E-01 0.003 
Cortical GM -0.008 0.015 5.90E-01 8.78E-01 0.000 
Total WM -0.016 0.014 2.45E-01 6.73E-01 0.000 
Subcortical GM -0.035 0.018 5.69E-02 5.04E-01 0.001 
Total Ventricular volume 0.007 0.028 7.86E-01 9.44E-01 -0.001 
Cerebellum volume -0.038 0.023 1.03E-01 6.28E-01 0.001 
Amygdala-hippocampus complex -0.008 0.020 7.08E-01 9.23E-01 0.000 
Caudate volume -0.044 0.026 7.58E-02 5.61E-01 0.001 
Putamen volume -0.034 0.025 1.82E-01 6.73E-01 0.001 
Thalamus volume -0.022 0.022 2.87E-01 6.73E-01 0.000 
MDD (prior= 0.1) 
TBV -0.060 0.025 1.78E-02* 2.92E-01 0.003 
Cortical GM -0.010 0.015 4.90E-01 8.06E-01 0.000 
Total WM -0.015 0.014 2.74E-01 6.73E-01 0.000 
Subcortical GM -0.035 0.018 5.52E-02 5.04E-01 0.001 
Total Ventricular volume 0.007 0.028 8.13E-01 9.57E-01 -0.001 
Cerebellum volume -0.042 0.023 7.27E-02 5.57E-01 0.001 
Amygdala-hippocampus complex -0.009 0.020 7.01E-01 9.23E-01 0.000 
Caudate volume -0.041 0.026 1.01E-01 6.23E-01 0.001 
Putamen volume -0.036 0.025 1.61E-01 6.73E-01 0.001 
Thalamus volume -0.022 0.022 2.82E-01 6.73E-01 0.000 
MDD (prior= 0.5) TBV -0.056 0.025 2.57E-02* 3.39E-01 0.003 
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Cortical GM -0.012 0.015 4.28E-01 7.68E-01 0.000 
Total WM -0.012 0.014 3.90E-01 7.42E-01 0.000 
Subcortical GM -0.032 0.018 7.86E-02 5.61E-01 0.001 
Total Ventricular volume 0.003 0.027 9.13E-01 9.98E-01 -0.001 
Cerebellum volume -0.047 0.023 4.17E-02* 4.61E-01 0.002 
Amygdala-hippocampus complex -0.007 0.020 7.60E-01 9.30E-01 0.000 
Caudate volume -0.035 0.026 1.60E-01 6.73E-01 0.001 
Putamen volume -0.037 0.025 1.50E-01 6.73E-01 0.001 
Thalamus volume -0.020 0.022 3.32E-01 6.91E-01 0.000 
MDD (prior= 1) 
TBV -0.056 0.025 2.73E-02* 3.48E-01 0.002 
Cortical GM -0.012 0.015 4.20E-01 7.59E-01 0.000 
Total WM -0.012 0.014 4.05E-01 7.46E-01 0.000 
Subcortical GM -0.032 0.018 7.89E-02 5.61E-01 0.001 
Total Ventricular volume 0.003 0.027 9.15E-01 9.98E-01 -0.001 
Cerebellum volume -0.048 0.023 3.98E-02* 4.52E-01 0.002 
Amygdala-hippocampus complex -0.007 0.020 7.64E-01 9.30E-01 0.000 
Caudate volume -0.034 0.026 1.65E-01 6.73E-01 0.001 
Putamen volume -0.037 0.025 1.43E-01 6.73E-01 0.001 
Thalamus volume -0.020 0.022 3.36E-01 6.91E-01 0.000 
MDD  (Infinitesimal prior) 
TBV -0.066 0.025 8.78E-03* 2.21E-01 0.004 
Cortical GM -0.006 0.015 6.73E-01 9.12E-01 0.000 
Total WM -0.019 0.014 1.85E-01 6.73E-01 0.000 
Subcortical GM -0.034 0.018 6.22E-02 5.21E-01 0.001 
Total Ventricular volume 0.022 0.027 4.33E-01 7.71E-01 0.000 
Cerebellum volume -0.037 0.023 1.09E-01 6.30E-01 0.001 
Amygdala-hippocampus complex 0.000 0.020 9.93E-01 9.98E-01 0.000 
Caudate volume -0.028 0.026 2.56E-01 6.73E-01 0.000 
Putamen volume -0.040 0.025 1.22E-01 6.66E-01 0.001 
Thalamus volume -0.029 0.022 1.49E-01 6.73E-01 0.000 
ADHD (prior= 0.01) 
TBV -0.033 0.025 1.94E-01 6.73E-01 0.000 
Cortical GM -0.007 0.015 6.49E-01 9.00E-01 0.000 
Total WM 0.018 0.014 1.93E-01 6.73E-01 0.000 
Subcortical GM -0.027 0.018 1.34E-01 6.73E-01 0.000 
Total Ventricular volume -0.030 0.027 2.81E-01 6.73E-01 0.000 
Cerebellum volume -0.029 0.023 2.10E-01 6.73E-01 0.000 
Amygdala-hippocampus complex 0.014 0.020 5.16E-01 8.30E-01 0.000 
Caudate volume -0.083 0.026 7.49E-04* 3.15E-02* 0.006 
Putamen volume -0.037 0.025 1.53E-01 6.73E-01 0.001 
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Thalamus volume -0.001 0.022 9.53E-01 9.98E-01 0.000 
ADHD (prior= 0.05) 
TBV -0.053 0.025 3.54E-02* 4.13E-01 0.002 
Cortical GM -0.014 0.015 3.50E-01 6.95E-01 0.000 
Total WM 0.015 0.014 2.92E-01 6.73E-01 0.000 
Subcortical GM -0.021 0.018 2.50E-01 6.73E-01 0.000 
Total Ventricular volume -0.023 0.027 4.09E-01 7.50E-01 0.000 
Cerebellum volume -0.036 0.023 1.19E-01 6.59E-01 0.001 
Amygdala-hippocampus complex 0.005 0.020 8.17E-01 9.58E-01 0.000 
Caudate volume -0.061 0.026 1.30E-02* 2.52E-01 0.003 
Putamen volume -0.025 0.025 3.24E-01 6.79E-01 0.000 
Thalamus volume 0.000 0.022 9.93E-01 9.98E-01 0.000 
ADHD (prior= 0.1) 
TBV -0.055 0.025 3.00E-02* 3.60E-01 0.002 
Cortical GM -0.016 0.015 2.84E-01 6.73E-01 0.000 
Total WM 0.014 0.014 3.19E-01 6.73E-01 0.000 
Subcortical GM -0.019 0.018 2.86E-01 6.73E-01 0.000 
Total Ventricular volume -0.016 0.027 5.56E-01 8.68E-01 0.000 
Cerebellum volume -0.037 0.023 1.06E-01 6.30E-01 0.001 
Amygdala-hippocampus complex 0.005 0.020 8.29E-01 9.64E-01 0.000 
Caudate volume -0.055 0.026 2.58E-02* 3.39E-01 0.002 
Putamen volume -0.024 0.025 3.41E-01 6.91E-01 0.000 
Thalamus volume -0.001 0.022 9.67E-01 9.98E-01 0.000 
ADHD (prior= 0.5) 
TBV -0.058 0.025 2.02E-02* 2.92E-01 0.003 
Cortical GM -0.016 0.015 2.85E-01 6.73E-01 0.000 
Total WM 0.012 0.014 3.98E-01 7.46E-01 0.000 
Subcortical GM -0.020 0.018 2.64E-01 6.73E-01 0.000 
Total Ventricular volume -0.008 0.027 7.71E-01 9.36E-01 -0.001 
Cerebellum volume -0.038 0.023 1.01E-01 6.23E-01 0.001 
Amygdala-hippocampus complex 0.001 0.020 9.60E-01 9.98E-01 0.000 
Caudate volume -0.049 0.026 4.72E-02* 4.72E-01 0.002 
Putamen volume -0.026 0.025 3.11E-01 6.73E-01 0.000 
Thalamus volume -0.003 0.022 8.71E-01 9.93E-01 0.000 
ADHD (prior= 1) 
TBV -0.059 0.025 2.01E-02* 2.92E-01 0.003 
Cortical GM -0.016 0.015 2.88E-01 6.73E-01 0.000 
Total WM 0.012 0.014 4.01E-01 7.46E-01 0.000 
Subcortical GM -0.020 0.018 2.70E-01 6.73E-01 0.000 
Total Ventricular volume -0.007 0.027 7.88E-01 9.44E-01 -0.001 
Cerebellum volume -0.038 0.023 9.69E-02 6.23E-01 0.001 
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Amygdala-hippocampus complex 0.001 0.020 9.70E-01 9.98E-01 0.000 
Caudate volume -0.048 0.025 5.26E-02 5.02E-01 0.002 
Putamen volume -0.026 0.025 3.12E-01 6.73E-01 0.000 
Thalamus volume -0.003 0.022 8.77E-01 9.93E-01 0.000 
ADHD  (Infinitesimal prior) 
TBV -0.069 0.025 5.98E-03* 1.93E-01 0.004 
Cortical GM -0.018 0.015 2.11E-01 6.73E-01 0.000 
Total WM 0.008 0.014 5.43E-01 8.51E-01 0.000 
Subcortical GM -0.023 0.018 2.04E-01 6.73E-01 0.000 
Total Ventricular volume 0.004 0.027 8.82E-01 9.96E-01 -0.001 
Cerebellum volume -0.019 0.023 4.11E-01 7.50E-01 0.000 
Amygdala-hippocampus complex -0.002 0.020 9.26E-01 9.98E-01 0.000 
Caudate volume -0.058 0.026 1.91E-02* 2.92E-01 0.003 
Putamen volume -0.029 0.025 2.61E-01 6.73E-01 0.000 
Thalamus volume -0.002 0.022 9.17E-01 9.98E-01 0.000 
ASD (prior= 0.01) 
TBV 0.048 0.025 5.62E-02 5.04E-01 0.002 
Cortical GM -0.005 0.015 7.48E-01 9.29E-01 0.000 
Total WM 0.000 0.014 9.96E-01 9.98E-01 0.000 
Subcortical GM 0.007 0.018 6.81E-01 9.16E-01 0.000 
Total Ventricular volume 0.028 0.027 3.15E-01 6.73E-01 0.000 
Cerebellum volume -0.013 0.023 5.75E-01 8.68E-01 0.000 
Amygdala-hippocampus complex -0.019 0.020 3.94E-01 7.42E-01 0.000 
Caudate volume -0.014 0.025 5.62E-01 8.68E-01 0.000 
Putamen volume 0.037 0.025 1.43E-01 6.73E-01 0.001 
Thalamus volume 0.019 0.022 3.37E-01 6.91E-01 0.000 
ASD (prior= 0.05) 
TBV 0.063 0.025 1.25E-02* 2.52E-01 0.003 
Cortical GM -0.005 0.015 7.28E-01 9.24E-01 0.000 
Total WM 0.006 0.014 6.70E-01 9.12E-01 0.000 
Subcortical GM 0.013 0.018 4.88E-01 8.06E-01 0.000 
Total Ventricular volume 0.033 0.027 2.35E-01 6.73E-01 0.000 
Cerebellum volume -0.003 0.023 8.93E-01 9.98E-01 -0.001 
Amygdala-hippocampus complex -0.011 0.020 6.05E-01 8.90E-01 0.000 
Caudate volume -0.009 0.026 7.02E-01 9.23E-01 -0.001 
Putamen volume 0.035 0.025 1.76E-01 6.73E-01 0.001 
Thalamus volume 0.022 0.022 2.71E-01 6.73E-01 0.000 
ASD (prior= 0.1) 
TBV 0.065 0.025 9.46E-03* 2.21E-01 0.004 
Cortical GM -0.005 0.015 7.18E-01 9.24E-01 0.000 
Total WM 0.006 0.014 6.49E-01 9.00E-01 0.000 
Subcortical GM 0.013 0.018 4.75E-01 7.89E-01 0.000 
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Total Ventricular volume 0.034 0.027 2.16E-01 6.73E-01 0.000 
Cerebellum volume -0.001 0.023 9.58E-01 9.98E-01 -0.001 
Amygdala-hippocampus complex -0.011 0.020 6.17E-01 8.90E-01 0.000 
Caudate volume -0.008 0.026 7.32E-01 9.25E-01 -0.001 
Putamen volume 0.034 0.025 1.86E-01 6.73E-01 0.000 
Thalamus volume 0.022 0.022 2.74E-01 6.73E-01 0.000 
ASD (prior= 0.5) 
TBV 0.067 0.025 7.89E-03* 2.21E-01 0.004 
Cortical GM -0.005 0.015 7.26E-01 9.24E-01 0.000 
Total WM 0.007 0.014 6.22E-01 8.90E-01 0.000 
Subcortical GM 0.013 0.018 4.59E-01 7.84E-01 0.000 
Total Ventricular volume 0.034 0.027 2.14E-01 6.73E-01 0.000 
Cerebellum volume 0.000 0.023 9.97E-01 9.98E-01 -0.001 
Amygdala-hippocampus complex -0.010 0.020 6.50E-01 9.00E-01 0.000 
Caudate volume -0.008 0.026 7.50E-01 9.29E-01 -0.001 
Putamen volume 0.033 0.025 1.96E-01 6.73E-01 0.000 
Thalamus volume 0.022 0.022 2.72E-01 6.73E-01 0.000 
ASD (prior= 1) 
TBV 0.067 0.025 7.75E-03* 2.21E-01 0.004 
Cortical GM -0.005 0.015 7.27E-01 9.24E-01 0.000 
Total WM 0.007 0.014 6.19E-01 8.90E-01 0.000 
Subcortical GM 0.014 0.018 4.58E-01 7.84E-01 0.000 
Total Ventricular volume 0.034 0.027 2.12E-01 6.73E-01 0.000 
Cerebellum volume 0.000 0.023 9.98E-01 9.98E-01 -0.001 
Amygdala-hippocampus complex -0.010 0.020 6.54E-01 9.00E-01 0.000 
Caudate volume -0.008 0.026 7.50E-01 9.29E-01 -0.001 
Putamen volume 0.033 0.025 1.96E-01 6.73E-01 0.000 
Thalamus volume 0.022 0.022 2.73E-01 6.73E-01 0.000 
ASD  (Infinitesimal prior) 
TBV 0.050 0.025 4.89E-02* 4.78E-01 0.002 
Cortical GM -0.008 0.015 5.94E-01 8.82E-01 0.000 
Total WM -0.001 0.014 9.32E-01 9.98E-01 0.000 
Subcortical GM 0.013 0.018 4.59E-01 7.84E-01 0.000 
Total Ventricular volume 0.034 0.027 2.19E-01 6.73E-01 0.000 
Cerebellum volume 0.004 0.023 8.75E-01 9.93E-01 -0.001 
Amygdala-hippocampus complex -0.012 0.020 5.74E-01 8.68E-01 0.000 
Caudate volume -0.007 0.025 7.89E-01 9.44E-01 -0.001 
Putamen volume 0.031 0.025 2.24E-01 6.73E-01 0.000 
Thalamus volume 0.027 0.022 1.79E-01 6.73E-01 0.000 
EA (prior= 0.01) TBV 0.087 
0.025 4.98E-04* 2.44E-02* 0.007 
Cortical GM 0.009 0.015 5.43E-01 8.51E-01 0.000 
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Total WM 0.000 0.014 9.78E-01 9.98E-01 0.000 
Subcortical GM 0.001 0.018 9.54E-01 9.98E-01 0.000 
Total Ventricular volume 0.012 0.027 6.56E-01 9.00E-01 -0.001 
Cerebellum volume 0.022 0.023 3.43E-01 6.91E-01 0.000 
Amygdala-hippocampus complex -0.008 0.020 7.11E-01 9.23E-01 0.000 
Caudate volume -0.009 0.026 7.05E-01 9.23E-01 -0.001 
Putamen volume -0.026 0.025 3.17E-01 6.73E-01 0.000 
Thalamus volume 0.015 0.022 4.52E-01 7.84E-01 0.000 
EA (prior= 0.05) 
TBV 0.031 0.025 2.20E-01 6.73E-01 0.000 
Cortical GM 0.007 0.015 6.55E-01 9.00E-01 0.000 
Total WM 0.001 0.014 9.59E-01 9.98E-01 0.000 
Subcortical GM 0.036 0.018 4.62E-02* 4.72E-01 0.001 
Total Ventricular volume 0.026 0.027 3.43E-01 6.91E-01 0.000 
Cerebellum volume 0.037 0.023 1.13E-01 6.30E-01 0.001 
Amygdala-hippocampus complex -0.002 0.020 9.12E-01 9.98E-01 0.000 
Caudate volume 0.039 0.025 1.10E-01 6.30E-01 0.001 
Putamen volume 0.062 0.025 1.55E-02* 2.84E-01 0.003 
Thalamus volume 0.022 0.022 2.80E-01 6.73E-01 0.000 
EA (prior= 0.1) 
TBV 0.134 0.025 9.36E-08* 1.35E-05* 0.017 
Cortical GM 0.011 0.015 4.67E-01 7.84E-01 0.000 
Total WM -0.023 0.014 1.11E-01 6.30E-01 0.000 
Subcortical GM 0.025 0.018 1.84E-01 6.73E-01 0.000 
Total Ventricular volume 0.025 0.028 3.76E-01 7.27E-01 0.000 
Cerebellum volume 0.047 0.023 4.66E-02* 4.72E-01 0.002 
Amygdala-hippocampus complex -0.028 0.020 2.21E-01 6.73E-01 0.000 
Caudate volume 0.032 0.026 1.98E-01 6.73E-01 0.000 
Putamen volume 0.023 0.025 3.81E-01 7.31E-01 0.000 
Thalamus volume 0.045 0.023 2.88E-02* 3.55E-01 0.002 
EA (prior= 0.5) 
TBV 0.135 0.025 7.12E-08* 1.35E-05* 0.018 
Cortical GM 0.012 0.015 4.42E-01 7.78E-01 0.000 
Total WM -0.016 0.014 2.45E-01 6.73E-01 0.000 
Subcortical GM 0.026 0.018 1.61E-01 6.73E-01 0.000 
Total Ventricular volume 0.030 0.028 2.80E-01 6.73E-01 0.000 
Cerebellum volume 0.045 0.023 5.76E-02 5.04E-01 0.001 
Amygdala-hippocampus complex -0.032 0.020 1.58E-01 6.73E-01 0.000 
Caudate volume 0.036 0.026 1.50E-01 6.73E-01 0.001 
Putamen volume 0.023 0.025 3.77E-01 7.27E-01 0.000 
Thalamus volume 0.051 0.023 1.32E-02* 2.52E-01 0.002 
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EA (prior= 1) 
TBV 0.134 0.025 9.65E-08* 1.35E-05* 0.017 
Cortical GM 0.012 0.015 4.21E-01 7.59E-01 0.000 
Total WM -0.015 0.014 2.92E-01 6.73E-01 0.000 
Subcortical GM 0.026 0.018 1.51E-01 6.73E-01 0.000 
Total Ventricular volume 0.031 0.028 2.72E-01 6.73E-01 0.000 
Cerebellum volume 0.044 0.023 6.02E-02 5.16E-01 0.001 
Amygdala-hippocampus complex -0.033 0.020 1.46E-01 6.73E-01 0.001 
Caudate volume 0.037 0.026 1.37E-01 6.73E-01 0.001 
Putamen volume 0.024 0.025 3.59E-01 7.02E-01 0.000 
Thalamus volume 0.052 0.023 1.12E-02* 2.48E-01 0.002 
EA  (Infinitesimal prior) 
TBV 0.129 0.025 2.66E-07* 2.79E-05* 0.016 
Cortical GM 0.017 0.015 2.60E-01 6.73E-01 0.000 
Total WM -0.017 0.014 2.21E-01 6.73E-01 0.000 
Subcortical GM 0.031 0.018 9.51E-02 6.23E-01 0.001 
Total Ventricular volume 0.017 0.028 5.36E-01 8.46E-01 0.000 
Cerebellum volume 0.037 0.023 1.10E-01 6.30E-01 0.001 
Amygdala-hippocampus complex -0.034 0.020 1.32E-01 6.73E-01 0.001 
Caudate volume 0.046 0.026 6.85E-02 5.53E-01 0.001 
Putamen volume 0.033 0.025 1.98E-01 6.73E-01 0.000 
Thalamus volume 0.049 0.023 1.70E-02* 2.92E-01 0.002 
Intelligence (prior= 0.01) 
TBV 0.023 0.025 3.54E-01 6.95E-01 0.000 
Cortical GM 0.014 0.015 3.52E-01 6.95E-01 0.000 
Total WM -0.005 0.014 7.18E-01 9.24E-01 0.000 
Subcortical GM 0.023 0.018 2.04E-01 6.73E-01 0.000 
Total Ventricular volume 0.023 0.027 4.05E-01 7.46E-01 0.000 
Cerebellum volume 0.068 0.023 3.19E-03* 1.11E-01 0.004 
Amygdala-hippocampus complex 0.002 0.020 9.23E-01 9.98E-01 0.000 
Caudate volume 0.041 0.026 1.01E-01 6.23E-01 0.001 
Putamen volume 0.019 0.025 4.66E-01 7.84E-01 0.000 
Thalamus volume 0.017 0.022 3.92E-01 7.42E-01 0.000 
Intelligence (prior= 0.05) 
TBV 0.027 0.025 2.90E-01 6.73E-01 0.000 
Cortical GM 0.015 0.015 3.14E-01 6.73E-01 0.000 
Total WM 0.001 0.014 9.42E-01 9.98E-01 0.000 
Subcortical GM 0.019 0.018 3.04E-01 6.73E-01 0.000 
Total Ventricular volume 0.020 0.027 4.71E-01 7.84E-01 0.000 
Cerebellum volume 0.068 0.023 3.04E-03* 1.11E-01 0.004 
Amygdala-hippocampus complex 0.016 0.020 4.60E-01 7.84E-01 0.000 
Caudate volume 0.028 0.025 2.51E-01 6.73E-01 0.000 
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Putamen volume 0.004 0.025 8.73E-01 9.93E-01 -0.001 
Thalamus volume 0.004 0.022 8.39E-01 9.66E-01 0.000 
Intelligence (prior= 0.1) 
TBV 0.087 0.025 5.22E-04* 2.44E-02* 0.007 
Cortical GM 0.007 0.015 6.16E-01 8.90E-01 0.000 
Total WM -0.004 0.014 7.98E-01 9.47E-01 0.000 
Subcortical GM 0.004 0.018 8.31E-01 9.64E-01 0.000 
Total Ventricular volume 0.002 0.027 9.33E-01 9.98E-01 -0.001 
Cerebellum volume 0.027 0.023 2.36E-01 6.73E-01 0.000 
Amygdala-hippocampus complex 0.026 0.020 2.39E-01 6.73E-01 0.000 
Caudate volume -0.016 0.026 5.15E-01 8.30E-01 0.000 
Putamen volume -0.014 0.025 5.72E-01 8.68E-01 0.000 
Thalamus volume 0.016 0.022 4.30E-01 7.68E-01 0.000 
Intelligence (prior= 0.5) 
TBV 0.124 0.025 6.87E-07* 5.77E-05* 0.015 
Cortical GM 0.018 0.015 2.33E-01 6.73E-01 0.000 
Total WM 0.001 0.014 9.41E-01 9.98E-01 0.000 
Subcortical GM 0.031 0.018 9.38E-02 6.23E-01 0.001 
Total Ventricular volume 0.004 0.028 8.75E-01 9.93E-01 -0.001 
Cerebellum volume 0.034 0.023 1.45E-01 6.73E-01 0.001 
Amygdala-hippocampus complex 0.030 0.020 1.77E-01 6.73E-01 0.000 
Caudate volume 0.023 0.026 3.51E-01 6.95E-01 0.000 
Putamen volume 0.022 0.025 3.88E-01 7.41E-01 0.000 
Thalamus volume 0.021 0.022 2.95E-01 6.73E-01 0.000 
Intelligence (prior= 1) 
TBV 0.121 0.025 1.32E-06* 7.90E-05* 0.014 
Cortical GM 0.015 0.015 3.13E-01 6.73E-01 0.000 
Total WM -0.001 0.014 9.30E-01 9.98E-01 0.000 
Subcortical GM 0.031 0.018 8.73E-02 6.11E-01 0.001 
Total Ventricular volume 0.001 0.028 9.83E-01 9.98E-01 -0.001 
Cerebellum volume 0.038 0.023 1.01E-01 6.23E-01 0.001 
Amygdala-hippocampus complex 0.026 0.020 2.41E-01 6.73E-01 0.000 
Caudate volume 0.030 0.026 2.27E-01 6.73E-01 0.000 
Putamen volume 0.020 0.025 4.46E-01 7.78E-01 0.000 
Thalamus volume 0.023 0.022 2.49E-01 6.73E-01 0.000 
Intelligence (Infinitesimal prior) 
TBV 0.122 0.025 1.18E-06* 7.90E-05* 0.014 
Cortical GM 0.016 0.015 2.89E-01 6.73E-01 0.000 
Total WM 0.002 0.014 9.05E-01 9.98E-01 0.000 
Subcortical GM 0.041 0.018 2.35E-02* 3.28E-01 0.001 
Total Ventricular volume 0.012 0.028 6.76E-01 9.13E-01 -0.001 
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Cerebellum volume 0.041 0.023 7.61E-02 5.61E-01 0.001 
Amygdala-hippocampus complex 0.018 0.020 4.14E-01 7.54E-01 0.000 
Caudate volume 0.046 0.026 6.32E-02 5.21E-01 0.001 
Putamen volume 0.026 0.025 3.09E-01 6.73E-01 0.000 
Thalamus volume 0.031 0.022 1.24E-01 6.66E-01 0.001 
Note: β, standardized coefficient; SE, standardized error; P-uncorr., uncorrected p-value; P-FDR, false discovery rate adjusted p-value; ΔAdj-R², difference between 
the adjusted R² of the full model (PGS + covariates) compared to the adjusted R² of the baseline model (only covariates). 
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Table S3. Mean and SD for polygenic scores for schizophrenia in the entire sample of participants with EU 
ancestry, included (n=1139) and excluded (n=1691) in the current study. P-value derived from t-test. 
  All EU children  Included Excluded P-value 
Prior=0.01 0.65 (2.57) 0.74 (2.56) 0.59 (2.58) 0.127 
Prior=0.05 -15.55 (0.90) -15.55 (0.87) -15.55 (0.92) 0.973 
Prior=0.1 -16.91 (0.69) -16.90 (0.68) -16.92 (0.70) 0.411 
Prior=0.5 -16.16 (0.46) -16.16 (0.45) -16.16 (0.47) 0.832 
Prior=1 -15.99 (0.44) -'15.99 (0.43) -15.99 (0.44) 0.911 
Infinitesimal prior -6.97 (0.22) -6.97 (0.22) -6.97 (0.22) 0.885 
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